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Background: Emergence of colonization and infection with vancomycin-resistant enterococci (VRE) has become a
worldwide challenge. To investigate whether the increasing incidence of VRE isolation can be correlated with use
of glycopeptides in the hospital setting, we conducted a hospital-wide two-year study in the university hospital of
Vienna.
Methods: Within the period from January 2011 through December 2012 all patients with isolation of invasive or
non-invasive VRE were retrospectively included. Specialty-specific data concerning the consumption of vancomycin
and teicoplanin, fluoroquinolones and third generation cephalosporins in defined daily doses (DDDs) from June
2010 through May 2012 were extracted from the hospital pharmacy computer system. To assess the relationship
between the usage of those antibiotics and the incidence of VRE (VRE-rate per 10 000 patients) a Poisson regression
was performed.
Findings: In the study period 266 patients were colonized or infected with VRE. Specialty-specific VRE isolation was
as follows: general surgical units (44 patients), bone marrow transplant unit (35 patients), general medical units (33
patients), cardiothoracic surgery (27 patients), nephrology (26 patients), haematooncology (22 patients), gastroenterology
(17 patients), urology (17 patients), and the infectious diseases unit (11 patients). Hospital-wide consumption of
glycopeptides was higher for teicoplanin than for vancomycin (26 242 versus 8677 DDDs). Specialty-specific VRE
incidence significantly increased with the use of glycopeptides, fluoroquinolones or third generation cephalosporins
(p < 0.001). The results of the Poisson regression for vancomycin (p = 0.0018) and teicoplanin (p < 0.0001) separately
were both highly significant. Spearman’s correlation coefficient indicated a strong correlation between the two
variables (rho = 0.8).
Conclusion: Overall usage of glycopeptides, fluoroquinolones or third generation cephalosporins contributed to the
emergence of VRE in the hospital setting.
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Enterococci are part of the gastrointestinal bacterial flora
and urogenital mucosa in healthy humans, but important
nosocomial pathogens in a variety of invasive infections
including endocarditis, bloodstream infections, wound
infections, and meningitis [1, 2].
Colonization and infection with vancomycin-resistant
enterococci (VRE), predominantly but not exclusively with
Enterococcus faecium, are emerging worldwide [3–5]. The
causes are multifactorial, but excessive usage of glycopep-
tides in animal husbandry and in human medicine may
further enhance the incidence of VRE [6, 7]. According
to the European Antimicrobial Resistance Surveillance
Report (EARS), the incidence of invasive Austrian iso-
lates of vancomycin-resistant E. faecium increased from
1.8 % in 2008 to 5.9 % in 2013 [5, 8]. Other neighbouring
countries such as Germany reported an even more dra-
matic increase to 14.5 % of the proportion of invasive
vancomycin-resistant E. faecium [8].
The aim of the present study was to investigate
whether this increasing incidence of VRE isolation in
our patients can be correlated with use of glycopeptides
in the hospital setting.
Methods
Study location and study population
The General Hospital of Vienna, Austria, is a 2133–bed
central hospital and the seat of the clinics of the Medical
University of Vienna. Each year more than 100 000
patients receive inpatient treatment and a total of 1.25
million patients attend the outpatient clinics [9]. The
university hospital is a renowned centre for solid
organ transplantation - Europe-wide leading in lung
transplantation-and haematooncology. After the study
was approved by the local ethics committee of the Medical
University of Vienna (EC No. 2004/2013), we retrospect-
ively included all patients in the hospital with any isolation
of VRE during the period of January 1, 2011 through
December 31, 2012. The study was retrospective and
observational with no interventions, therefore the need
for informed consent was waived. The numbers of pa-
tients colonized or infected with VRE isolated from sur-
veillance cultures and invasive cultures (from blood or
other normally sterile body sites) were obtained from the
hospital’s database (RDA/Archimed ALERT, Department
of Infection Control and Hospital Epidemiology) for
patients with multi-drug resistant pathogens.
In case of VRE screening selective enrichment media
(brain-heart infusion containing vancomycin and ceftazi-
dime as well as chromID VRE, bioMérieux, Marcy
l’Etoile, France) were inoculated, while clinical samples
for non-targeted culture were processed following stand-
ard procedures dependent on the type of specimen, i.e.
non-selective enrichment broth (brain-heart infusion)was included only in case of material from primary ster-
ile body sites. Enterococcus faecalis was identified by the
formation of black colonies on tellurit agar plates, while
other Enterococcus species were identified by VITEK 2
GP (bioMérieux) or MALDI-TOF mass spectrometry
(Bruker Daltonics GmbH, Bremen, Germany). If the
vancomycin and teicoplanin disc diffusion test according
to the current version of the EUCAST methodology [10]
displayed glycopeptide resistance, E tests for both sub-
stances following the manufacturer’s instructions (bio-
Mérieux) were performed. Presence of the VanA or
VanB phenotype was deduced from the observed min-
imal inhibitory concentrations of vancomycin and teico-
planin [11].
For avoidance of nosocomial transmissions, a targeted
risk adjusted screening policy with subsequent isolation
(single room or, if not possible, strict contact isolation)
of patients colonized or infected with VRE is imple-
mented at our institution.
Antibiotic usage
Glycopeptides, fluoroquinolones and third generation
cephalosporins were classified according to the anatomical
therapeutic chemical (ATC) system. In our institution the
following agents were used: vancomycin, teicoplanin,
ciprofloxacin, levofloxacin, moxifloxacin, ceftriaxone, cef-
otaxime, ceftazidime and cefixime. Hospital-wide and
specialty-specific data on consumption of those antibiotics
were derived from the hospital pharmacy for the period
from June 1, 2010 through and including May 31, 2012.
Antibiotic usage was measured in defined daily doses
(DDDs). In accordance with the ATC classification/DDD
index 2013, the glycopeptide DDDs used were vanco-
mycin 2 g and teicoplanin 0.4 g, the fluoroquinolone
DDDs used were levofloxacin 0.5 g, moxifloxacin 0.4 g
and ciprofloxacin 1 g for oral administration or 0.5 g for
parenteral administration, the third generation cephalo-
sporin DDDs used were ceftriaxone 2 g, cefotaxime 4 g,
ceftazidime 4 g and cefixime 0.4 g [12].
Statistical analysis
In order to assess the relationship between the antibiotic
usage and the incidence of VRE (VRE-rate per 10 000
patients), a Poisson regression model was fitted with the
number of VRE-positive patients as the dependent vari-
able, logarithm of the mean usage of glycopeptides,
fluoroquinolones or third generation cephalosporins as
independent variable and the total number of patients in
each unit as an offset.
As in a previous surveillance study by Kritsotakis et al.
a dynamic relationship between antimicrobial use of gly-
copeptides and an increase in the VRE incidence was
identified with average delays between 2 and 6 months
[13], we selected to compare time-delayed 2-year periods
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isolation.
Model diagnostics revealed that the non-transformed
mean usage did not fit the data well due to a high lever-
age point (influential point). Further to control for pos-
sible violations of the distribution assumptions, White’s
robust covariance estimator was calculated [14]. Z-tests
were performed using the coefficients of the Poisson
model and the robust standard errors. P-values of ≤0.05
were considered to be statistically significant. All calcula-
tions were performed using R 3.0.2.
Results
In the pre-study period from 2004 through 2010, a con-
tinuous increase in the number of VRE-positive patients
was detected in the hospital, from a single documented
case of VRE in 2004 (corresponding to 0.001 patients
per 10 000 admissions), 67 cases of VRE in 2007 (corre-
sponding to 0.066 patients per 10 000 admissions) to a
peak of 129 VRE-positive patients in 2010 (correspond-
ing to 0.125 patients per 10 000 admissions).
During the subsequent two-year study period, a total
of 99 635 patients were admitted to the hospital in 2011
and 102 083 in 2012. The overall VRE incidence was
0.131 per 10 000 admissions in the first year and 0.156
per 10 000 admissions in the second year. Among these
patients, 261 patients were colonized or infected with a
single VRE species (E. faecium, n = 258; E. faecalis, n = 3),
and five patients were colonized with 2 VRE species
(E. faecium, n = 5; E. faecalis, n = 4; E. raffinosus, n = 1).
The VanA phenotype was detected in the VRE isolates of
234 (88 %) patients and VanB phenotype in 33 (12 %)
patients.
As shown in the Table 1, most patients were only colo-
nized by non-invasive VRE-isolates, which were isolated
from screening cultures (faeces or rectal swab, followed
by skin swab, oropharyngeal swab). Among 87 patients
with proven VRE-infection, 18 patients developed VRE
bacteraemia with E. faecium.
A total of 201 patients were admitted to inpatient
wards, 52 patients to intensive care units and 13 were
outpatients. The specialties most frequently involvedTable 1 Hospital-wide trends in colonizing and invasive vancomycin
2011 through 2012
Species Annual total no. (%) patients with VRE Annual no. (%) p
2011 2012 2011
Any Enterococcus sp. 123 (100) 143 (100) 87 (71)
E. faecium 123 (100) 140 (98) 87 (71)
E. faecalis 3 (2.4) 4 (2.8) 3 (2.4)
E. raffinosus 1 (0.8) 0 1 (0.8)
In case of isolation of more than one Enterococcus spp. in one patient, the patient wwere general surgical (44 patients), followed by the bone
marrow transplantation (BMT) unit (35 patients), general
medicine (33 patients), cardiothoracic surgery (27 patients),
nephrology (26 patients), haematooncology (22 patients),
gastroenterology (17 patients), urology (17 patients), and
the infectious diseases unit (11 patients) (Fig. 1).
The total hospital-wide numbers of antimicrobial
DDDs were as follows:
8677 for vancomycin, 26 242 for teicoplanin, 64 788
for ciprofloxacin, 32 264 for levofloxacin, 22 155 for
moxifloxacin, 13 080 for ceftriaxone, 10 910 for cefotaxime,
6958 for ceftazidime, and 1651 for cefixime. Total con-
sumption of glycopeptides, fluoroquinolones and third
generation cephalosporins per specialty is shown in Fig. 2.
Specialty-specific VRE incidence significantly increased
with the use of glycopeptides, fluoroquinolones or third
generation cephalosporins (p < 0.001). Figure 3 shows a
non-linear relationship with a dramatic increase in the
incidence of VRE with high glycopeptide, fluoroquinolone
or third generation cephalosporin usage. The results of
the Poisson regression for vancomycin (p = 0.0018) and
teicoplanin separately (p < 0.0001) were both highly sig-
nificant. Spearman’s correlation coefficient indicated a
strong correlation between the two variables (rho = 0.8).
Discussion
In the present study we identified a positive non-linear
relationship between the specialty-specific isolation of
VRE and total glycopeptide, fluoroquinolone or third
generation cephalosporin consumption. Most patients
with VRE-positive cultures were simply colonized, but
6.8 % experienced bloodstream infection caused by
vancomycin-resistant E. faecium. Despite less clinical
relevance of VRE compared to infections caused by
methicillin-resistant Staphylococcus aureus (MRSA),
management of invasive VRE infections is challenging
because of limited treatment options. Furthermore, en-
terococcal bacteraemia was associated with increased
risk of death in allogeneic haematopoietic stem cell
transplant recipients [15]. During a 7-year surveillance
study, a dynamic relationship was identified between
antimicrobial use of glycopeptides, fluoroquinolones,-resistant Enterococcus (VRE) species during the study period
atients only colonized with VRE Annual no. (%) patients infected with VRE
2012 2011 2012
92 (64) 36 (29) 51 (36)
90 (63) 36 (29) 50 (35)
2 (1.4) 0 2 (1.4)
0 0 0
as only counted once for the category any Enterococcus sp.
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Total no. patients with VRE 
Fig. 1 Specialty-specific isolation of VRE in the General Hospital of
Vienna during the two-year study period
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in the incidence of VRE, with average delays between 2
and 6 months [13]. In contrast, other studies do not report
such a direct relationship between glycopeptide use and
VRE isolation [16] but have shown an association between0 10000
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BMT unit 


















Fig. 2 Specialty-specific usage of glycopeptides, fluoroquinolones and third
the period June 2010 to June 2012a higher incidence of VRE-bloodstream infection and previ-
ous hospital use of other, non-glycopeptide, antimicrobials
such as the third-generation cephalosporin ceftriaxone
[17]. In a recent systematic review it was not possible to
conclusively determine a potential role for reduction of
vancomycin use in controlling VRE [18]. But, in a retro-
spective case–control study in a university hospital of
Korea, vancomycin use significantly prolonged the duration
of VRE carriage among intensive care patients already colo-
nized with vancomycin-resistant E. faecium [19]. However,
because of the high tenacity of VRE in the environment,
measures other than reduction of glycopeptide use, such as
isolation of patients and enforced environmental cleaning,
are necessary to control its spread [20]. Patients who are at
risk are consequently screened at admittance and isolated
in single rooms. We also hypothesize that in our hospital
the departments most frequently involved treat patients
with chronic diseases for a long period of time, and VRE
emerge due to glycopeptide use.
Vancomycin and teicoplanin are used therapeutically in
our hospital to treat invasive infections with gram-positive
multi-drug resistant microorganisms or as empirical
therapy in severe sepsis or septic shock in intensive care
and immunosuppressed patients. During the period 2000
through 2011, vancomycin was used most frequently in
our institution as first-line treatment in patients with
MRSA bacteraemia, followed by teicoplanin [21]. 20000 30000 40000 
ed daily doses of antibiotics 
Glycopeptides 
Fluoroquinolones 
3rd gen cephalosporins 
generation cephalosporins in the General Hospital of Vienna during
Fig. 3 Non-linear relationship between the usage of glycopeptides (a), fluoroquinolones (b) or third generation cephalosporins (c) and VRE-rate per 10
000 patients. The points indicate observations and the solid line the fit of the Poisson regression model
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caused by Clostridium difficile, oral glycopeptides can
promote acquisition of gastrointestinal VRE [22], whereas
the use of other oral antimicrobial agents against C.
difficile, such as fidaxomicin, decrease the risk of VRE
acquisition [23].
A limitation of our study was that we could not assess
the impact of oral versus intravenous use of glycopep-
tides on the incidence of VRE separately. During the ob-
servation period, only the intravenous formulations of
vancomycin and teicoplanin were provided for oral use,
because no oral formulations were available.Conclusions
We demonstrated a positive non-linear relationship be-
tween the specialty-specific isolation of VRE and glycopep-
tide, fluoroquinolone or third generation cephalosporin
usage in the University Hospital of Vienna. Although VRE
incidence is increasing in our institution, the increase re-
mains moderate, and is probably controlled by infection
control measures. Nevertheless, to minimize the spread of
glycopeptide-resistant Enterococcus species in the hospital
setting, the implementation of a program for prudent use
of glycopeptides, fluoroquinolones and third generation
cephalosporins is warranted.
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